Gabrielle Truitt1,2,3, Haley Gittleman1,2,4, Rebecca Leece5, Quinn T Ostrom1,6, Carol Kruchko1, Terri S Armstrong7, Mark R Gilbert7, Jill S Barnholtz-Sloan8,9,10. 1. Central Brain Tumor Registry of the United States, Hinsdale, IL, USA. 2. Case Comprehensive Cancer Center, Cleveland, OH, USA. 3. Department of Bioethics, Case Western Reserve University School of Medicine, Cleveland, OH, USA. 4. Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA. 5. Case Western Reserve University School of Medicine, Cleveland, OH, USA. 6. Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. 7. Neuro Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 8. Central Brain Tumor Registry of the United States, Hinsdale, IL, USA. jsb42@case.edu. 9. Case Comprehensive Cancer Center, Cleveland, OH, USA. jsb42@case.edu. 10. Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA. jsb42@case.edu.
Abstract
PURPOSE: Population-based cancer statistics, including histology-specific incidence, prevalence, and survival are essential to evaluating the total burden due to disease in a population. The National Cancer Institute's (NCI) Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) was developed to better understand tumor biology and patient outcomes for 12 selected brain and other central nervous system (CNS) tumor histologies that are rare in adults to improve approaches to care and treatment. The aim of this study was to determine the incidence, prevalence, and survival of these selected rare histologies. METHODS: Data from the Central Brain Tumor Registry of the United States (CBTRUS) from 2000 to 2014 were used to calculate average annual age-adjusted incidence rates (AAIR) per 100,000 population overall and by sex, race, ethnicity, and age. NCI's Surveillance, Epidemiology and End Results (SEER) data were used to calculate relative survival (RS) estimates. Point prevalence for 2014 was estimated using annual age-specific incidence and survival from CBTRUS and SEER, respectively. RESULTS: Overall AAIR was 1.47 per 100,000 for all 12 rare histologies combined, with the highest histology-specific incidence in oligodendrogliomas (AAIR = 0.40/100,000). Overall, most histologies were more common in males, adults (age 40 + ), Whites, and non-Hispanics. Ependymomas were the most prevalent histology at 4.11 per 100,000; followed by oligodendrogliomas at 3.68 per 100,000. Relative survival at 1-, 5-, and 10-years was 82.3%, 64.0%, and 55.4%, respectively for all 12 selected brain and other CNS tumor types combined. Ependymomas had the highest RS (1-year = 94.2%, 5-year = 83.9%, 10-year = 78.6%) and gliosarcomas had the lowest relative survival rate (1-year = 42.5%, 5-year = 5.6%, 10-year = 2.9%) at all three time points. CONCLUSIONS: Incidence and prevalence of these rare brain and other CNS tumor histologies have not been previously reported. Along with survival, these data provide a statistical foundation to understand the impact of these cancers and provide important disease-specific data for the design of prospective clinical trials.
PURPOSE: Population-based cancer statistics, including histology-specific incidence, prevalence, and survival are essential to evaluating the total burden due to disease in a population. The National Cancer Institute's (NCI) Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) was developed to better understand tumor biology and patient outcomes for 12 selected brain and other central nervous system (CNS) tumor histologies that are rare in adults to improve approaches to care and treatment. The aim of this study was to determine the incidence, prevalence, and survival of these selected rare histologies. METHODS: Data from the Central Brain Tumor Registry of the United States (CBTRUS) from 2000 to 2014 were used to calculate average annual age-adjusted incidence rates (AAIR) per 100,000 population overall and by sex, race, ethnicity, and age. NCI's Surveillance, Epidemiology and End Results (SEER) data were used to calculate relative survival (RS) estimates. Point prevalence for 2014 was estimated using annual age-specific incidence and survival from CBTRUS and SEER, respectively. RESULTS: Overall AAIR was 1.47 per 100,000 for all 12 rare histologies combined, with the highest histology-specific incidence in oligodendrogliomas (AAIR = 0.40/100,000). Overall, most histologies were more common in males, adults (age 40 + ), Whites, and non-Hispanics. Ependymomas were the most prevalent histology at 4.11 per 100,000; followed by oligodendrogliomas at 3.68 per 100,000. Relative survival at 1-, 5-, and 10-years was 82.3%, 64.0%, and 55.4%, respectively for all 12 selected brain and other CNS tumor types combined. Ependymomas had the highest RS (1-year = 94.2%, 5-year = 83.9%, 10-year = 78.6%) and gliosarcomas had the lowest relative survival rate (1-year = 42.5%, 5-year = 5.6%, 10-year = 2.9%) at all three time points. CONCLUSIONS: Incidence and prevalence of these rare brain and other CNS tumor histologies have not been previously reported. Along with survival, these data provide a statistical foundation to understand the impact of these cancers and provide important disease-specific data for the design of prospective clinical trials.
Authors: Gregory T Armstrong; Peter C Phillips; Lucy B Rorke-Adams; Alexander R Judkins; A Russell Localio; Michael J Fisher Journal: Cancer Date: 2006-10-01 Impact factor: 6.860
Authors: Marta Penas-Prado; Brett J Theeler; Brittany Cordeiro; Ira J Dunkel; Peter Hau; Anita Mahajan; Giles W Robinson; Nicole Willmarth; Orwa Aboud; Kenneth Aldape; John A Butman; Amar Gajjar; William Kelly; Ganesh Rao; Margarita Raygada; Christine Siegel; Carlos G Romo; Terri S Armstrong; Mark R Gilbert Journal: Neurooncol Adv Date: 2020-08-17
Authors: Michael Bockmayr; Kim Harnisch; Lara C Pohl; Leonille Schweizer; Theresa Mohme; Meik Körner; Malik Alawi; Abigail K Suwala; Mario M Dorostkar; Camelia M Monoranu; Martin Hasselblatt; Annika K Wefers; David Capper; Jürgen Hench; Stephan Frank; Timothy E Richardson; Ivy Tran; Elisa Liu; Matija Snuderl; Lara Engertsberger; Martin Benesch; Andreas von Deimling; Denise Obrecht; Martin Mynarek; Stefan Rutkowski; Markus Glatzel; Julia E Neumann; Ulrich Schüller Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029
Authors: Antonio Dono; Kristin Alfaro-Munoz; Yuanqing Yan; Carlos A Lopez-Garcia; Zaid Soomro; Garret Williford; Takeshi Takayasu; Lindsay Robell; Nazanin K Majd; John de Groot; Yoshua Esquenazi; Carlos Kamiya-Matsuoka; Leomar Y Ballester Journal: Neurosurgery Date: 2022-05-01 Impact factor: 5.315
Authors: Mark R Gilbert; Ying Yuan; Jimin Wu; Tito Mendoza; Elizabeth Vera; Antonio Omuro; Frank Lieberman; H Ian Robins; Elizabeth R Gerstner; Jing Wu; Patrick Y Wen; Tom Mikkelsen; Kenneth Aldape; Terri S Armstrong Journal: Neuro Oncol Date: 2021-03-25 Impact factor: 12.300
Authors: Nazanin K Majd; Maximilan Mastall; Heather Lin; Seyede Shiva Dibaj; Kenneth R Hess; Ying Yuan; Manuela Martin-Bejarano Garcia; Gregory N Fuller; Kristin D Alfaro; Maria K Gule-Monroe; Jason T Huse; Soumen Khatua; Ganesh Rao; David I Sandberg; Jeffrey S Wefel; Debra N Yeboa; Arnold C Paulino; Susan L McGovern; Wafik Zaky; Anita Mahajan; Dima Suki; Shiao-Pei Weathers; Rebecca A Harriso; John F De Groo; Vinay K Puduvalli; Marta Penas-Prado Journal: Neurooncol Adv Date: 2021-06-22
Authors: Cas S Dejonckheere; Alexander M C Böhner; David Koch; Leonard C Schmeel; Ulrich Herrlinger; Hartmut Vatter; Matthias Schneider; Patrick Schuss; Frank A Giordano; Mümtaz A Köksal Journal: Strahlenther Onkol Date: 2021-12-22 Impact factor: 3.621